April 26, 2018 / 5:01 AM / 8 months ago

BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome

April 26 (Reuters) - Zealand Pharma A/S:

* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME

* SAYS PIVOTAL PHASE 3 TRIAL IS ON TRACK FOR INITIATION IN Q3 2018

* ZEALAND EXPECTS TO INITIATE PIVOTAL PHASE 3 TRIAL IN Q3 2018

* SCIENTIFIC ADVICE WITH EUROPEAN MEDICINES AGENCY (EMA) IS ONGOING WITH AN EXPECTED OUTCOME BY MID-2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below